Details for Patent: 8,906,890

Which drugs does patent 8,906,890 protect, and when does it expire?

Patent 8,906,890 protects ANGELIQ and is included in one NDA.

This patent has twenty-one patent family members in sixteen countries.

Summary for Patent: 8,906,890

Title:	Very low-dosed solid oral dosage forms for HRT
Abstract:	The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
Inventor(s):	Mletzko; Stephan (Berlin, DE), Schurmann; Rolf (Teltow, DE), Gude; Kerstin (Birkenwerder, DE)
Assignee:	Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:	13/087,701
Patent Claim Types: see list of patent claims	Composition; Dosage form; Use;

Drugs Protected by US Patent 8,906,890

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Hlthcare	ANGELIQ	drospirenone; estradiol	TABLET;ORAL	021355-001	Feb 29, 2012		RX	Yes	No			Y

Foreign Priority and PCT Information for Patent: 8,906,890

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	10160072	Apr 15, 2010

International Family Members for US Patent 8,906,890

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	080912
Australia	2011240102
Brazil	112012026115
Canada	2795801
China	102985070
Colombia	6630107